ABO-101

Phase 2Small molecule

AArbor Biotechnologies

ABO-101 is one of 2 small molecule programs targeting Primary Hyperoxaluria Type 1. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Hyperoxaluria Type 1Recruiting

Primary Hyperoxaluria Type 1Phase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Primary Hyperoxaluria Type 1

#DrugCompanyPhaseTrials

ABO-101

AArbor Biotechnologies

Phase 2

1 2

Rivfloza

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2043

Phase 1/2Recruiting

Primary Hyperoxaluria Type 1

NCT06839235

Clinical

Trials by Indication[1]

Primary Hyperoxaluria Type 11 trial

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

Recruiting·AArbor Biotechnologies·Phase 1/2·NCT06839235·23 enrolled

Long-term Follow-up1 trial

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

Terminated·AAbeona Therapeutics, Inc··NCT04655911·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ABO-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABO-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABO-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arbor Biotechnologies company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AArbor Biotechnologies

ABO-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2043

Trials by Indication[1]

Primary Hyperoxaluria Type 11 trial

Long-term Follow-up1 trial

References

Drug Info

Quick Facts

Related News